aTyr Pharma (Nasdaq: ATYR) will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026 at 8:00 AM EDT. President and CEO Sanjay S. Shukla, M.D., M.S. will deliver a corporate presentation and meet one-on-one with registered investors.
A live webcast will be available on the company’s Investor section and a replay will remain on the aTyr website for at least 90 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ATYR
+1.14%
13 alerts
+1.14%Session close to close
+7.2%Peak in 2 hr 31 min
$108.77MMarket Cap
0.7xRel. Volume
In the Feb 18 session, ATYR gained 1.14%, reflecting a mild positive market reaction.
Argus tracked a peak move of +7.2% during that session.
Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
This announcement highlights aTyr’s upcoming corporate presentation at a major healthcare conference...
Analysis
This announcement highlights aTyr’s upcoming corporate presentation at a major healthcare conference and continued investor outreach. It follows a series of clinically focused updates on efzofitimod, including a Phase 3 study that missed its primary endpoint yet showed encouraging secondary signals. Investors may track how management frames the program’s status, the FDA Type C meeting scheduled for mid‑April 2026, and broader pipeline or financing commentary during the March 11, 2026 presentation.
Key Figures
Conference dates:March 8–11, 2026Presentation date:Wednesday, March 11, 2026Presentation time:8:00 am EDT+1 more
4 metrics
Conference datesMarch 8–11, 2026Leerink Partners Global Healthcare Conference schedule
Presentation dateWednesday, March 11, 2026Scheduled corporate presentation
Presentation time8:00 am EDTLeerink conference presentation slot
Replay availability90 daysWebcast replay available on company website
EFZO-FIT topline results with non‑significant primary endpoint outcome.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows ATYR shares typically trading lower on negative clinical and earnings updates, and even drifting down on neutral conference announcements.
Recent Company History
Over the last six months, ATYR’s key news flow has centered on efzofitimod’s Phase 3 EFZO-FIT data and follow-up regulatory and investor communications. The topline readout on Sep 15, 2025 showed a missed primary endpoint and drove a -83.17% move, with subsequent ERS data, Q3 results, and a scheduled FDA Type C meeting all followed by additional negative reactions. Prior conference news on Nov 10, 2025 also saw shares down, underscoring a pattern of weakness around updates.
"engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform"
tRNA synthetase is an enzyme that matches each building block of proteins (an amino acid) to its correct carrier molecule called transfer RNA (tRNA), ensuring proteins are assembled correctly in cells. Think of it as a factory worker who puts the right part onto the right delivery tray before assembly; if it fails, proteins can be made incorrectly. Investors watch these enzymes because they can be drug targets, biomarkers of disease, or sources of genetic disorders that affect a company’s therapeutic or safety profile.
fibrosismedical
"new therapies for fibrosis and inflammation"
Fibrosis is the process where excess scar tissue forms in an organ or tissue, often as a response to injury or long-term damage. This buildup can impair normal function, much like thickening insulation reduces the effectiveness of a wire. For investors, fibrosis is significant because it can signal ongoing health issues that may lead to increased medical costs or influence a company’s performance in healthcare-related sectors.
interstitial lung diseasemedical
"in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders"
A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.
immunomodulatormedical
"efzofitimod, a novel biologic immunomodulator in clinical development for the treatment"
An immunomodulator is a medicine or therapy that changes how the immune system behaves—either boosting its ability to fight infections and cancer or calming it to reduce harmful inflammation. Investors watch these products because their success in clinical trials, safety and side-effect profiles, and regulatory approvals can open large markets or limit sales; think of them as tools that tweak the body’s defense system, with outcomes that strongly affect a drug maker’s future revenue and stock value.
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL.
Details of the presentation appear below:
Conference: Leerink Partners Global Healthcare Conference Date: Wednesday, March 11, 2026 Time: 8:00am EDT Location: Miami, FL Format: Corporate Presentation
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Sr. Director, Investor Relations and Public Affairs
When will aTyr Pharma (ATYR) present at the Leerink Partners Global Healthcare Conference?
aTyr Pharma will present on Wednesday, March 11, 2026 at 8:00 AM EDT. According to the company, the presentation is a corporate format and will occur in Miami during the conference running March 8–11, 2026.
Who will present for aTyr Pharma (ATYR) at the March 11, 2026 conference?
President and CEO Sanjay S. Shukla, M.D., M.S. will present on behalf of aTyr Pharma. According to the company, management will also be available for one-on-one investor meetings for registered attendees.
Will aTyr Pharma (ATYR) provide a webcast of its March 11, 2026 presentation?
Yes, a live webcast will be available on the company’s Investor section of its website. According to the company, a replay of the presentation will be posted on the aTyr website for at least 90 days after the event.
How can investors arrange one-on-one meetings with aTyr Pharma (ATYR) management at the conference?
Investors must be registered attendees to schedule one-on-one meetings with aTyr management. According to the company, interested investors should use attendee registration and contact investor relations for details.
Where and when is the Leerink Partners Global Healthcare Conference taking place for aTyr Pharma (ATYR)?
The conference runs March 8–11, 2026 in Miami, FL, with aTyr presenting on March 11. According to the company, the presentation is part of the conference agenda and open to registered attendees.
Where can I find the aTyr Pharma (ATYR) presentation replay after the March 11, 2026 event?
A replay will be available on the aTyr website for at least 90 days after the event. According to the company, the replay will be posted in the Investor section at the company website.
